Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Purdue Pharma LP |
---|---|
Information provided by: | Purdue Pharma LP |
ClinicalTrials.gov Identifier: | NCT00531427 |
The objective of this study is to determine the analgesic efficacy and safety of Buprenorphine Transdermal System (BTDS) 10 and 20 compared to placebo in opioid-naïve subjects with moderate to severe chronic pain due to OA of the knee. The double-blind treatment intervention duration is 12 weeks, during which time supplemental analgesic medication (immediate-release oxycodone for the first 6 days post randomization and acetaminophen or ibuprofen for the remainder of the double-blind phase) will be provided to all subjects in addition to study drug.
Condition | Intervention | Phase |
---|---|---|
Chronic Pain Osteoarthritis of the Knee |
Drug: Buprenorphine Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Randomized, Double-Blind, Placebo-Controlled With Open-Label Run-in Assessing Efficacy, Tolerability,Safety of BTDS 10 or 20 Compared to Placebo in Opioid-naïve Subjects w/Moderate to Severe,Chronic Pain Due to OA of Knee |
Estimated Enrollment: | 520 |
Study Start Date: | September 2007 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Buprenorphine transdermal delivery system 10 and 20 worn for 7 days
|
Drug: Buprenorphine
transdermal delivery system 10 and 20 worn for 7 days
|
2: Placebo Comparator |
Drug: Placebo
transdermal delivery system (placebo) worn for 7 days
|
Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic settings for the relief of moderate to severe pain. BTDS is a transdermal system formulation that is designed to deliver a consistent and a steady dose of buprenorphine over a 7-day period with limited blood concentration fluctuation.
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-specific inclusion/exclusion criteria may apply.
Contact: Karen Ventrella | 1-800-745-7445 ext 7387 | karen.ventrella@pharma.com |
Responsible Party: | Purdue Pharma L.P. ( Medical Monitor ) |
Study ID Numbers: | BUP3025 |
Study First Received: | September 17, 2007 |
Last Updated: | December 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00531427 |
Health Authority: | United States: Food and Drug Administration |
Chronic pain, OA of the knee, opioid, transdermal |
Signs and Symptoms Osteoarthritis, Knee Buprenorphine Musculoskeletal Diseases Osteoarthritis |
Joint Diseases Arthritis Neurologic Manifestations Pain Rheumatic Diseases |
Sensory System Agents Therapeutic Uses Narcotic Antagonists Physiological Effects of Drugs Nervous System Diseases Central Nervous System Depressants |
Narcotics Peripheral Nervous System Agents Analgesics Central Nervous System Agents Pharmacologic Actions Analgesics, Opioid |